“Narcolepsy – Pipeline Review, H1 2015
Summary
Global Markets Direct’s, ‘Narcolepsy – Pipeline Review, H1 2015’, provides an overview of the Narcolepsy’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Narcolepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Narcolepsy and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
– The report provides a snapshot of the global therapeutic landscape of Narcolepsy
– The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
– The report reviews key players involved in the therapeutics development for Narcolepsy and enlists all their major and minor projects
– The report summarizes all the dormant and discontinued pipeline projects
– A review of the Narcolepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
– Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
– A detailed assessment of monotherapy and combination therapy pipeline projects
– Coverage of the Narcolepsy pipeline on the basis of target, MoA, route of administration and molecule type
– Latest news and deals relating related to pipeline products
Reasons to buy
– Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
– Develop strategic initiatives by understanding the focus areas of leading companies
– Identify and understand important and diverse types of therapeutics under development for Narcolepsy
– Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
– Devise corrective measures for pipeline projects by understanding Narcolepsy pipeline depth and focus of Indication therapeutics
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
– Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline”
“Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Narcolepsy Overview 7
Therapeutics Development 8
Pipeline Products for Narcolepsy – Overview 8
Pipeline Products for Narcolepsy – Comparative Analysis 9
Narcolepsy – Therapeutics under Development by Companies 10
Narcolepsy – Therapeutics under Investigation by Universities/Institutes 11
Narcolepsy – Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Narcolepsy – Products under Development by Companies 15
Narcolepsy – Products under Investigation by Universities/Institutes 16
Narcolepsy – Companies Involved in Therapeutics Development 17
Bioprojet SCR 17
Evotec AG 18
Flamel Technologies S.A. 19
Grupo Ferrer Internacional, S.A. 20
Jazz Pharmaceuticals plc 21
SK Biopharmaceuticals Co., Ltd. 22
Taisho Pharmaceutical Co., Ltd. 23
Narcolepsy – Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 30
Drug Profiles 31
arbaclofen – Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Drugs to Agonize Orexin Receptor for Narcolepsy – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
EVT-501 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
JZP-386 – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
pitolisant – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
SKL-N05 – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules to Agonize Orexin Receptor for Narcolepsy and EDS – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
sodium oxybate – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
sodium oxybate – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
THN-102 – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
TS-091 – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Narcolepsy – Recent Pipeline Updates 46
Narcolepsy – Dormant Projects 49
Narcolepsy – Discontinued Products 50
Narcolepsy – Product Development Milestones 51
Featured News & Press Releases 51
May 07, 2015: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update 51
Dec 19, 2014: Flamel Technologies Announces Positive Results of a Second Clinical Trial With Micropump Sodium Oxybate 51
Dec 09, 2014: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update 52
Dec 02, 2014: Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Trial of Xyrem (Sodium Oxybate) In Children And Adolescents Who Have Narcolepsy With Cataplexy 52
Jul 21, 2014: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide a Phase 1 Clinical Trial Update on JZP-386 53
Jun 02, 2014: Jazz Pharmaceuticals Presents JZP-110 Phase 2b Data For The Treatment Of EDS Symptoms In Adults With Narcolepsy 53
May 27, 2014: Jazz Pharmaceuticals To Present Data On Compound In Sleep Pipeline During APSS Annual SLEEP Meeting 54
May 07, 2014: Sleep Researchers at SRI International Identify Promising New Treatment for Narcolepsy 54
Apr 07, 2014: Flamel Technologies Announces Positive Results of a First-in-Man Clinical Trial With Micropump Sodium Oxybate 55
Jun 03, 2013: Aerial BioPharma Announces Presentation Of ADX-NO5 Results At SLEEP 2013 Meeting 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59″
“List of Tables
Number of Products under Development for Narcolepsy, H1 2015 8
Number of Products under Development for Narcolepsy – Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Products under Investigation by Universities/Institutes, H1 2015 16
Narcolepsy – Pipeline by Bioprojet SCR, H1 2015 17
Narcolepsy – Pipeline by Evotec AG, H1 2015 18
Narcolepsy – Pipeline by Flamel Technologies S.A., H1 2015 19
Narcolepsy – Pipeline by Grupo Ferrer Internacional, S.A., H1 2015 20
Narcolepsy – Pipeline by Jazz Pharmaceuticals plc, H1 2015 21
Narcolepsy – Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2015 22
Narcolepsy – Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2015 23
Assessment by Monotherapy Products, H1 2015 24
Number of Products by Stage and Target, H1 2015 26
Number of Products by Stage and Mechanism of Action, H1 2015 28
Number of Products by Stage and Route of Administration, H1 2015 29
Number of Products by Stage and Molecule Type, H1 2015 30
Narcolepsy Therapeutics – Recent Pipeline Updates, H1 2015 46
Narcolepsy – Dormant Projects, H1 2015 49
Narcolepsy – Discontinued Products, H1 2015 50″
“List of Figures
Number of Products under Development for Narcolepsy, H1 2015 8
Number of Products under Development for Narcolepsy – Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Late Stage Development, H1 2015 12
Comparative Analysis by Clinical Stage Development, H1 2015 13
Comparative Analysis by Early Stage Products, H1 2015 14
Assessment by Monotherapy Products, H1 2015 24
Number of Products by Top 10 Targets, H1 2015 25
Number of Products by Stage and Top 10 Targets, H1 2015 26
Number of Products by Top 10 Mechanism of Actions, H1 2015 27
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 28
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 29
Number of Products by Stage and Top 10 Molecule Types, H1 2015 30″
“Bioprojet SCR
Evotec AG
Flamel Technologies S.A.
Grupo Ferrer Internacional, S.A.
Jazz Pharmaceuticals plc
SK Biopharmaceuticals Co., Ltd.
Taisho Pharmaceutical Co., Ltd.”
